Kymera Therapeutics, Inc.
-
Ticker
KYMR
-
Industry
Biotechnology More
-
Sector
Healthcare More
- 51-200 Employees
- Based in Watertown, Massachusetts
Kymera is a biopharmaceutical company pioneering the field of targeted protein degradation, a transformative approach to address disease targets and pathways inaccessible with conventional therapeutics. Kymera’s Pegasus platform is a powerful drug discovery engine, advancing novel small molecule programs designed to harness the body’s innate protein recycling machinery to degrade dysregulated
…More, disease-causing proteins. With a focus on undrugged nodes in validated pathways, Kymera is advancing a pipeline of novel therapeutic candidates designed to address the most promising targets and provide patients with more effective treatments. Kymera’s initial programs target IRAK4, IRAKIMiD, and STAT3 within the IL-1R/TLR or JAK/STAT pathways, and the MDM2 oncoprotein, providing the opportunity to treat patients with a broad range of immune-inflammatory diseases, hematologic malignancies, and solid tumors.
REPORT RATINGS
5.0 / 5.0 (1)
Kymera Therapeutics, Inc. reports have an aggregate usefulness score of 5.0 based on 1 reviews.
Kymera Therapeutics, Inc.
Most Recent Annual Report
MOST RECENT
2023 Annual Report and Form 10K
Older/Archived Annual Reports